Riccardo Vergaro
@drvergaro.bsky.social
Resident in Anesthesiology, Intensive care & Pain medicine - IRCCS San Matteo, Pavia
WO2026030396 anti-ROR1 ADCs linking a tumor-restricted ROR1 antibody to camptothecin derivatives. Targeting ROR1, overexpressed in CLL, NHL, and several solid tumors, enables selective delivery of topoisomerase I inhibitors, expanding beyond microtubule/PBD-based ROR1 ADCs.
[Credit: SystImmune]
[Credit: SystImmune]
February 16, 2026 at 6:54 AM
WO2026030396 anti-ROR1 ADCs linking a tumor-restricted ROR1 antibody to camptothecin derivatives. Targeting ROR1, overexpressed in CLL, NHL, and several solid tumors, enables selective delivery of topoisomerase I inhibitors, expanding beyond microtubule/PBD-based ROR1 ADCs.
[Credit: SystImmune]
[Credit: SystImmune]
WO2026028158 TRAP bifunctional agents that bind anti-AAV neutralising antibodies and hepatocyte asialoglycoprotein receptor, triggering receptor-mediated endocytosis and degradation. This targeted antibody clearance restores AAV transduction and may permit redosing w/o systemic immunosuppression.
February 15, 2026 at 1:48 PM
WO2026028158 TRAP bifunctional agents that bind anti-AAV neutralising antibodies and hepatocyte asialoglycoprotein receptor, triggering receptor-mediated endocytosis and degradation. This targeted antibody clearance restores AAV transduction and may permit redosing w/o systemic immunosuppression.
WO2026030331 ADCs delivering dual PI3K/mTOR inhibitors (e.g., omipalisib) to tumors. By inhibiting all class I PI3K isoforms and both mTORC1/2, they overcome feedback activation and enhance pathway suppression, reducing systemic toxicity via tumor-targeted antibody conjugation.
[Credit: Corellia AI]
[Credit: Corellia AI]
February 14, 2026 at 10:47 AM
WO2026030331 ADCs delivering dual PI3K/mTOR inhibitors (e.g., omipalisib) to tumors. By inhibiting all class I PI3K isoforms and both mTORC1/2, they overcome feedback activation and enhance pathway suppression, reducing systemic toxicity via tumor-targeted antibody conjugation.
[Credit: Corellia AI]
[Credit: Corellia AI]
WO2026024136 describes anti-B2M antibodies that selectively target pathological MHC-I/B2M complexes. By disrupting aberrant B2M–MHC-I interactions, they modulate antigen presentation and immune signaling for treating cancer, autoimmunity, transplant rejection, and B2M amyloidosis.
[Credit: 울산대학교]
[Credit: 울산대학교]
February 13, 2026 at 7:21 AM
WO2026024136 describes anti-B2M antibodies that selectively target pathological MHC-I/B2M complexes. By disrupting aberrant B2M–MHC-I interactions, they modulate antigen presentation and immune signaling for treating cancer, autoimmunity, transplant rejection, and B2M amyloidosis.
[Credit: 울산대학교]
[Credit: 울산대학교]
WO2026024841 protease-activated CD3×MUC1 bispecific antibodies with dual masking of both arms. They remain inactive systemically, activate within the tumour microenvironment, reducing toxicity and maintaining efficacy, including in low-MUC1 tumours. The platform is modular for other tumour antigens.
February 12, 2026 at 12:33 PM
WO2026024841 protease-activated CD3×MUC1 bispecific antibodies with dual masking of both arms. They remain inactive systemically, activate within the tumour microenvironment, reducing toxicity and maintaining efficacy, including in low-MUC1 tumours. The platform is modular for other tumour antigens.
WO2026025059 a Fc-engineered CD24×CD3 bispecific IgG antibodies targeting CD24-overexpressing solid and hematologic tumors. By attenuating Fc effector functions, they favor CD3-mediated T-cell cytotoxicity. Preclinical data show potent, dose-, CD24- and T-cell-dependent tumor killing.
[Credit: UoV]
[Credit: UoV]
February 11, 2026 at 12:39 PM
WO2026025059 a Fc-engineered CD24×CD3 bispecific IgG antibodies targeting CD24-overexpressing solid and hematologic tumors. By attenuating Fc effector functions, they favor CD3-mediated T-cell cytotoxicity. Preclinical data show potent, dose-, CD24- and T-cell-dependent tumor killing.
[Credit: UoV]
[Credit: UoV]
WO2026022350 describes multispecific antibodies co-targeting PD-L1 and PVRIG to overcome tumor immune evasion. Dual blockade reactivates exhausted CD8+ T cells, enhances NK cytotoxicity, and restores antitumor immunity by disrupting complementary immunosuppressive pathways.
[Credit: Orion Pharma]
[Credit: Orion Pharma]
February 10, 2026 at 1:32 PM
WO2026022350 describes multispecific antibodies co-targeting PD-L1 and PVRIG to overcome tumor immune evasion. Dual blockade reactivates exhausted CD8+ T cells, enhances NK cytotoxicity, and restores antitumor immunity by disrupting complementary immunosuppressive pathways.
[Credit: Orion Pharma]
[Credit: Orion Pharma]
WO2026017779 describes high-affinity Fc-free VHH antibodies targeting erythrocyte basigin (CD147), blocking the essential PfRH5–basigin interaction and preventing Plasmodium falciparum merozoite invasion, offering a safe host-directed blood-stage malaria strategy.
[Credit: Max Planck GZFDW E.V.]
[Credit: Max Planck GZFDW E.V.]
February 9, 2026 at 9:55 AM
WO2026017779 describes high-affinity Fc-free VHH antibodies targeting erythrocyte basigin (CD147), blocking the essential PfRH5–basigin interaction and preventing Plasmodium falciparum merozoite invasion, offering a safe host-directed blood-stage malaria strategy.
[Credit: Max Planck GZFDW E.V.]
[Credit: Max Planck GZFDW E.V.]
WO2026021993 describes a tumor-selective ADC against TA-MUC1, a cancer-specific hypoglycosylated MUC1 glycoform prevalent in epithelial tumors. Highly specific anti-TA-MUC1 antibodies linked to cytotoxic payloads enhance efficacy and safety by sparing normal tissues.
[Credit: JCU Mainz]
[Credit: JCU Mainz]
February 8, 2026 at 4:17 PM
WO2026021993 describes a tumor-selective ADC against TA-MUC1, a cancer-specific hypoglycosylated MUC1 glycoform prevalent in epithelial tumors. Highly specific anti-TA-MUC1 antibodies linked to cytotoxic payloads enhance efficacy and safety by sparing normal tissues.
[Credit: JCU Mainz]
[Credit: JCU Mainz]
Vss minimization guided development of the CCR4 antagonist RPT193, targeting blood CCR4 to block Th2 chemotaxis. Medicinal chemistry optimized Vss, clearance, potency and bioavailability, yielding zelnecirnon, efficacious preclinically; phase 2 stopped for hepatotoxicity but validated the mechanism.
February 7, 2026 at 10:28 AM
Vss minimization guided development of the CCR4 antagonist RPT193, targeting blood CCR4 to block Th2 chemotaxis. Medicinal chemistry optimized Vss, clearance, potency and bioavailability, yielding zelnecirnon, efficacious preclinically; phase 2 stopped for hepatotoxicity but validated the mechanism.
WO2026016811 discloses a portfolio of humanized anti-TfR1 (CD71) antibodies engineered for high affinity and specificity while avoiding Tf competition, receptor down-regulation, toxicity, and immunogenicity, enabling controlled binding and internalisation of a challenging oncology target.
February 6, 2026 at 9:22 AM
WO2026016811 discloses a portfolio of humanized anti-TfR1 (CD71) antibodies engineered for high affinity and specificity while avoiding Tf competition, receptor down-regulation, toxicity, and immunogenicity, enabling controlled binding and internalisation of a challenging oncology target.
WO2026017120 describes trispecific antibodies co-targeting CDH17 and EGFR on GI tumours while directly engaging CD16A on NK cells, combining tumour selectivity, EGFR blockade, and Fc-independent ADCC to enhance efficacy and overcome resistance.
[Credit: Fortvita Biologics]
[Credit: Fortvita Biologics]
February 5, 2026 at 1:47 PM
WO2026017120 describes trispecific antibodies co-targeting CDH17 and EGFR on GI tumours while directly engaging CD16A on NK cells, combining tumour selectivity, EGFR blockade, and Fc-independent ADCC to enhance efficacy and overcome resistance.
[Credit: Fortvita Biologics]
[Credit: Fortvita Biologics]
First-in-class CRBN-recruiting molecular glue CCT412020 selectively degrades TBK1 via a non-canonical dimer-interface binding mode. TBK1 loss enhances TNF/IFN-mediated immunogenic cell death, sensitizing tumors to immune checkpoint blockade.
[Credit: John J. Caldwell]
[Credit: John J. Caldwell]
February 4, 2026 at 12:45 PM
First-in-class CRBN-recruiting molecular glue CCT412020 selectively degrades TBK1 via a non-canonical dimer-interface binding mode. TBK1 loss enhances TNF/IFN-mediated immunogenic cell death, sensitizing tumors to immune checkpoint blockade.
[Credit: John J. Caldwell]
[Credit: John J. Caldwell]
WO2026015981 describes degrader-antibody conjugates that selectively degrade TYK2 and/or JAK1 in pathogenic T-cell subsets. By combining antibody-mediated cell targeting with targeted protein degradation, the approach improves efficacy and safety over systemic JAK inhibitors in autoimmune diseases.
February 3, 2026 at 7:09 AM
WO2026015981 describes degrader-antibody conjugates that selectively degrade TYK2 and/or JAK1 in pathogenic T-cell subsets. By combining antibody-mediated cell targeting with targeted protein degradation, the approach improves efficacy and safety over systemic JAK inhibitors in autoimmune diseases.
WO2026019667 describes a trispecific antibody that co-engages a disease antigen, CD3, and CD28, delivering coordinated activation and costimulation to T cells. This restores physiological T-cell signaling, improving cytotoxicity, persistence, and safety over CD3 bispecifics.
[Credit: JN Biosciences]
[Credit: JN Biosciences]
February 2, 2026 at 11:37 AM
WO2026019667 describes a trispecific antibody that co-engages a disease antigen, CD3, and CD28, delivering coordinated activation and costimulation to T cells. This restores physiological T-cell signaling, improving cytotoxicity, persistence, and safety over CD3 bispecifics.
[Credit: JN Biosciences]
[Credit: JN Biosciences]
WO2026006919 shows that antibody discovery platforms optimized for monospecifics cannot efficiently explore the vast format–geometry–epitope space of multispecific antibodies, where function depends on precise valency, spatial arrangement, affinity and developability, requiring new paradigms.
February 1, 2026 at 11:04 AM
WO2026006919 shows that antibody discovery platforms optimized for monospecifics cannot efficiently explore the vast format–geometry–epitope space of multispecific antibodies, where function depends on precise valency, spatial arrangement, affinity and developability, requiring new paradigms.
WO2026018064 discloses a multispecific multi-drug ADC that binds ≥2 tumor targets and carries two distinct cytotoxic payloads on separate linkers, enabling dual-mechanism killing, improved selectivity and potency, reduced resistance, and an improved therapeutic index.
[Credit: Merus N.V.]
[Credit: Merus N.V.]
January 31, 2026 at 2:02 PM
WO2026018064 discloses a multispecific multi-drug ADC that binds ≥2 tumor targets and carries two distinct cytotoxic payloads on separate linkers, enabling dual-mechanism killing, improved selectivity and potency, reduced resistance, and an improved therapeutic index.
[Credit: Merus N.V.]
[Credit: Merus N.V.]
Ceralasertib is an oral ATR inhibitor blocking CHK1-mediated DNA damage checkpoints, increasing tumor sensitivity to replication stress and DNA-damaging therapy. It may also activate cGAS-STING immunity, supporting use in resistant solid tumors.
[Credit: Hardaker E.L. et al]
[Credit: Hardaker E.L. et al]
January 30, 2026 at 6:55 AM
Ceralasertib is an oral ATR inhibitor blocking CHK1-mediated DNA damage checkpoints, increasing tumor sensitivity to replication stress and DNA-damaging therapy. It may also activate cGAS-STING immunity, supporting use in resistant solid tumors.
[Credit: Hardaker E.L. et al]
[Credit: Hardaker E.L. et al]
WO2026015574 describes anti-WNT2 antibody–drug conjugates bearing auristatin payloads (e.g. MMAE) that selectively kill WNT2-overexpressing tumors. By targeting tumor-associated WNT2 rather than blocking signaling, ADCs show strong xenograft efficacy with reduced systemic toxicity.
[Credit: UCSF]
[Credit: UCSF]
January 29, 2026 at 11:43 AM
WO2026015574 describes anti-WNT2 antibody–drug conjugates bearing auristatin payloads (e.g. MMAE) that selectively kill WNT2-overexpressing tumors. By targeting tumor-associated WNT2 rather than blocking signaling, ADCs show strong xenograft efficacy with reduced systemic toxicity.
[Credit: UCSF]
[Credit: UCSF]
WO2026005714 discloses an Asx-independent PAL-based ligation platform enabling site-specific attachment of two distinct payloads to one protein. Dual PAL or hybrid chemical/enzymatic strategies yield homogeneous dual-payload ADCs with defined stoichiometry and high efficiency.
[Credit: Nanyang TUS]
[Credit: Nanyang TUS]
January 28, 2026 at 12:58 PM
WO2026005714 discloses an Asx-independent PAL-based ligation platform enabling site-specific attachment of two distinct payloads to one protein. Dual PAL or hybrid chemical/enzymatic strategies yield homogeneous dual-payload ADCs with defined stoichiometry and high efficiency.
[Credit: Nanyang TUS]
[Credit: Nanyang TUS]
WO2026013234 discloses multi-payload ADCs where one antibody carries cell-permeable and non-permeable TOP1 inhibitors, optionally plus a third toxin (e.g. MMAE). Distinct permeability within one ADC yields synergistic tumour killing exceeding single-payload TOP1-ADCs.
[Credit: Araris Biotech AG]
[Credit: Araris Biotech AG]
January 27, 2026 at 1:41 PM
WO2026013234 discloses multi-payload ADCs where one antibody carries cell-permeable and non-permeable TOP1 inhibitors, optionally plus a third toxin (e.g. MMAE). Distinct permeability within one ADC yields synergistic tumour killing exceeding single-payload TOP1-ADCs.
[Credit: Araris Biotech AG]
[Credit: Araris Biotech AG]
WO2026011391 describes anti-CD276 (B7-H3) ADCs for B7-H3–overexpressing cancers, exploiting tumor and tumor-endothelial selectivity. A CH1/hinge cysteine (~IMGT 142) enables site-specific conjugation, yielding stable, homogeneous ADCs (DAR≈4) with improved manufacturability.
[Credit: Bliss Biopharm]
[Credit: Bliss Biopharm]
January 26, 2026 at 9:42 AM
WO2026011391 describes anti-CD276 (B7-H3) ADCs for B7-H3–overexpressing cancers, exploiting tumor and tumor-endothelial selectivity. A CH1/hinge cysteine (~IMGT 142) enables site-specific conjugation, yielding stable, homogeneous ADCs (DAR≈4) with improved manufacturability.
[Credit: Bliss Biopharm]
[Credit: Bliss Biopharm]
Triple-action PROTAC (TAPTAC) reactivates WT p53 by blocking HDM2–p53, overcoming HDMX suppression, and repurposing HDM2 to degrade BET oncoproteins. It shows durable antitumor efficacy across WT p53 solid and hematologic models, with selectivity for HDM2-dependent cancers.
[Credit: N.Bae]
[Credit: N.Bae]
January 25, 2026 at 1:25 PM
Triple-action PROTAC (TAPTAC) reactivates WT p53 by blocking HDM2–p53, overcoming HDMX suppression, and repurposing HDM2 to degrade BET oncoproteins. It shows durable antitumor efficacy across WT p53 solid and hematologic models, with selectivity for HDM2-dependent cancers.
[Credit: N.Bae]
[Credit: N.Bae]
Roche describes a new modular P329G-engager antibody platform where tumour-binding adaptor IgGs assemble in vivo with anti-P329G immune engagers. Activity is strictly target-dependent, extensible across effector classes, and shown in vitro/in vivo, though less potent than direct bispecifics.
January 24, 2026 at 11:09 AM
Roche describes a new modular P329G-engager antibody platform where tumour-binding adaptor IgGs assemble in vivo with anti-P329G immune engagers. Activity is strictly target-dependent, extensible across effector classes, and shown in vitro/in vivo, though less potent than direct bispecifics.
Two studies show induced proximity rewires biology via bifunctional BRD4–PARP ligands (DD-CIP1/2, PCIP-1). These act through event-driven pharmacology, uncoupling target binding from potency, yielding in vivo antitumour activity and distinct from RIPTACs.
[Credit: R.Hjerpe]
[Credit: R.Hjerpe]
January 23, 2026 at 7:12 AM
Two studies show induced proximity rewires biology via bifunctional BRD4–PARP ligands (DD-CIP1/2, PCIP-1). These act through event-driven pharmacology, uncoupling target binding from potency, yielding in vivo antitumour activity and distinct from RIPTACs.
[Credit: R.Hjerpe]
[Credit: R.Hjerpe]